Evidence map›Paper›PMID 34820175›Full record

ArticlePeerJ2021

Commercial utilities and future perspective of nanomedicines.

Rishabha Malviya, Shivkanya Fuloria, Swati Verma, Vetriselvan Subramaniyan, Kathiresan V Sathasivam, Vinoth Kumarasamy, Darnal Hari Kumar, Shalini Vellasamy, Dhanalekshmi Unnikrishnan Meenakshi, Shikha Yadav and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Rishabha MalviyaDepartment of Pharmacy, SMAS, Galgotias University, Greater Noida, Uttar Pradesh, India.
Shivkanya FuloriaFaculty of Pharmacy & Centre of Excellence for Biomaterials Engineering, AIMST University, Bedong, Kedah, Malaysia.
Swati VermaDepartment of Pharmacy, SMAS, Galgotias University, Greater Noida, Uttar Pradesh, India.
Vetriselvan SubramaniyanFaculty of Medicine, Bioscience and Nursing, MAHSA University, Bandar Saujana Putra, Selangor, Malaysia.
Kathiresan V SathasivamFaculty of Applied Science & Centre of Excellence for Biomaterials Engineering, AIMST University, Bedong, Kedah, Malaysia.
Vinoth KumarasamyFaculty of Medicine, Bioscience and Nursing, MAHSA University, Bandar Saujana Putra, Selangor, Malaysia.ORCID 0000-0002-8895-1796
Darnal Hari KumarJeffrey Cheah Cheshire School of Medicine & Health Sciences, Monash University, Selangor, Malaysia.ORCID 0000-0002-8116-0967
Shalini VellasamyFaculty of Medicine, Bioscience and Nursing, MAHSA University, Bandar Saujana Putra, Selangor, Malaysia.
Dhanalekshmi Unnikrishnan MeenakshiCollege of Pharmacy, University of Science and Technology, Muscat, Oman.
Shikha YadavDepartment of Pharmacy, SMAS, Galgotias University, Greater Noida, Uttar Pradesh, India.
Akanksha SharmaDepartment of Pharmacy, SMAS, Galgotias University, Greater Noida, Uttar Pradesh, India.
Neeraj Kumar FuloriaFaculty of Pharmacy & Centre of Excellence for Biomaterials Engineering, AIMST University, Bedong, Kedah, Malaysia.
Galgotias University · INAIMST University · MYMahsa University · MYMonash University Malaysia · MYMuscat College · OM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present review aims to describe the commercial utilities and future perspectives of nanomedicines. Nanomedicines are intended to increase precision medicine and decrease the adverse effects on the patient. Nanomedicines are produced, engineered, and industrialized at the cellular, chemical, and macromolecular levels. This study describes the various aspects of nanomedicine such as governing outlooks over high use of nanomedicine, regulatory advancements for nanomedicines, standards, and guidelines for nanomedicines as per Therapeutic Goods Administration (TGA). This review also focuses on the patents and clinical trials based on nanoformulation, along with nanomedicines utilization as drug therapy and their market value. The present study concludes that nanomedicines are of high importance in biomedical and pharmaceutical production and offer better therapeutic effects especially in the case of drugs that possess low aqueous solubility. The factual data presented in this study will assist the researchers and health care professionals in understanding the applications of nanomedicine for better diagnosis and effective treatment of a disease.

Indexed as

Disease treatmentDrug therapyNanomedicinesNanoparticlesNanotechnology

Identifiers

PMID34820175
PMCPMC8607930
OpenAlexW3216222963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.